CoVPN 3502 REGENERON
Brief description of study
This is A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-Cov-2 Infection in Household Contacts of Individuals Infected with SARS-CoV-2
Detailed description of study
This research study is looking at experimental drugs to prevent the COVID-19 disease from occurring in people who have been exposed to the SARS-CoV-2 virus. The study drugs target the virus that causes COVID-19 and are designed to make it harder for the virus to infect you. The goals of the study include seeing whether the study drugs lower infection by the virus, whether they reduce the need for medical visits and the amount of time you spend away from your day-to-day activities (i.e., work, school, caring for others) due to COVID-19, and whether they can cause side effects.
If you agree to join, you will be in the study for about 32 weeks. You will be randomly assigned to receive 1 dose of either the study drugs or a placebo. This will be done subcutaneously (under the skin). During the study, you will have tests done at several times, including having nasopharyngeal swabs taken, as well as having blood drawn.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
COVID,COVID19,healthy volunteers
-
Age: Between 18 Years - 99 Years
-
Gender: All
*Currently living with someone who tested positive for COVID-19 disease in the past 96 hours.
Updated on
07 Jul 2023.
Study ID: 844137
